$MNKD
MANNKIND CORP Stock $mnkd

$mnkd Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-K Financial Statement

#000156459018003510 Filed on February 27, 2018

Income Statement

Concept	2017 Q4	2017 Q3	2017 Q2
Revenue	$4.530M	$2.043M	$2.163M
YoY Change	-63.48%	-98.74%
Cost Of Revenue	$5.000M	$4.575M	$5.086M
YoY Change	-57.63%	5.63%	25.74%
Gross Profit	-$500.0K	-$2.532M	-$2.923M
YoY Change	-183.33%	-101.6%	-27.74%
Gross Profit Margin	-11.04%	-123.94%	-135.14%
Selling, General & Admin	$23.30M	$17.73M	$18.57M
YoY Change	52.29%	34.94%	67.11%
% of Gross Profit
Research & Development	$3.500M	$4.400M	$3.123M
YoY Change	118.75%	12.33%	-27.54%
% of Gross Profit
Depreciation & Amortization	$820.0K	$454.0K	$450.0K
YoY Change	-22.64%	-23.95%	-23.6%
% of Gross Profit
Operating Expenses	$26.70M	$17.73M	$21.69M
YoY Change	58.93%	3.95%	40.65%
Operating Profit	-$27.20M	-$28.18M	-$31.57M
YoY Change	67.9%	-123.83%	65.09%
Interest Expense	-$4.700M	-$8.400M	-$9.700M
YoY Change	67.86%	-201.2%	97.96%
% of Operating Profit
Other Income/Expense, Net	$0.00	-$4.707M	-$3.768M
YoY Change		-156.77%	-65.22%
Pretax Income	-$32.70M	-$32.89M	-$35.34M
YoY Change	-160.56%	-125.99%	17.96%
Income Tax	$100.0K	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$32.78M	-$32.89M	-$35.34M
YoY Change	-160.74%	-125.99%	17.96%
Net Earnings / Revenue	-723.71%	-1609.69%	-1633.8%
Basic Earnings Per Share	-$0.28	-$0.31	-$0.35
Diluted Earnings Per Share	-$0.28	-$0.31	-$0.35
COMMON SHARES
Basic Shares Outstanding	116.5M	104.7M	99.86M
Diluted Shares Outstanding	116.5M	104.7M	99.86M

Balance Sheet

Concept	2017 Q4	2017 Q3	2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$43.90M	$20.10M	$43.40M
YoY Change	91.7%	-43.38%	-31.87%
Cash & Equivalents	$43.95M	$20.09M	$43.38M
Short-Term Investments
Other Short-Term Assets	$7.800M	$3.600M	$3.100M
YoY Change	-63.55%	-25.0%	-87.14%
Inventory	$2.657M	$3.129M	$3.172M
Prepaid Expenses
Receivables	$2.789M	$1.804M	$1.312M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$57.22M	$28.63M	$50.93M
YoY Change	-26.16%	-41.1%	-43.89%
LONG-TERM ASSETS
Property, Plant & Equipment	$26.92M	$27.37M	$27.92M
YoY Change	-6.93%	-41.54%	-41.12%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$437.0K	$480.0K	$523.0K
YoY Change	-32.56%	-31.62%	-58.09%
Total Long-Term Assets	$27.36M	$27.85M	$28.44M
YoY Change	-7.49%	-41.39%	-41.56%
TOTAL ASSETS
Total Short-Term Assets	$57.22M	$28.63M	$50.93M
Total Long-Term Assets	$27.36M	$27.85M	$28.44M
Total Assets	$84.58M	$56.48M	$79.37M
YoY Change	-21.0%	-41.24%	-43.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.984M	$5.283M	$6.541M
YoY Change	114.04%	3.73%	129.59%
Accrued Expenses	$12.45M	$12.49M	$9.076M
YoY Change	56.85%	-11.8%	-11.47%
Deferred Revenue	$250.0K
YoY Change
Short-Term Debt	$52.70M	$57.90M	$57.50M
YoY Change	-26.09%	-18.34%	-23.84%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$87.60M	$91.50M	$85.87M
YoY Change	-4.84%	-13.54%	-70.36%
LONG-TERM LIABILITIES
Long-Term Debt	$104.1M	$107.3M	$107.3M
YoY Change	34.84%	-27.7%	-27.06%
Other Long-Term Liabilities	$107.6M	$108.7M	$107.4M
YoY Change	-11.37%	524.82%	544.35%
Total Long-Term Liabilities	$211.7M	$216.0M	$214.7M
YoY Change	6.6%	1141.59%	1188.1%
TOTAL LIABILITIES
Total Short-Term Liabilities	$87.60M	$91.50M	$85.87M
Total Long-Term Liabilities	$211.7M	$216.0M	$214.7M
Total Liabilities	$299.3M	$307.5M	$300.6M
YoY Change	2.98%	-8.16%	-40.59%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.855B		-$2.789B
YoY Change	4.29%		-4.41%
Common Stock	$2.640B		$2.568B
YoY Change	3.37%		0.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$214.7M	-$251.0M	-$221.2M
YoY Change
Total Liabilities & Shareholders Equity	$84.58M	$56.50M	$79.37M
YoY Change	-21.0%	-41.23%	-43.07%

Cashflow Statement

Concept	2017 Q4	2017 Q3	2017 Q2
OPERATING ACTIVITIES
Net Income	-$32.78M	-$32.89M	-$35.34M
YoY Change	-160.74%	-125.99%	17.96%
Depreciation, Depletion And Amortization	$820.0K	$454.0K	$450.0K
YoY Change	-22.64%	-23.95%	-23.6%
Cash From Operating Activities	-$29.98M	-$23.27M	-$20.04M
YoY Change	135.14%	0.87%	74.11%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$30.00K
YoY Change
Cash From Investing Activities	$0.00	$0.00	$30.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	58.24M	-20.00K	15.42M
YoY Change	48433.33%	-99.61%	-67.6%
NET CHANGE
Cash From Operating Activities	-29.98M	-23.27M	-20.04M
Cash From Investing Activities	0.000	0.000	30.00K
Cash From Financing Activities	58.24M	-20.00K	15.42M
Net Change In Cash	28.26M	-23.29M	-4.590M
YoY Change	-323.75%	-17.41%	-112.72%
FREE CASH FLOW
Cash From Operating Activities	-$29.98M	-$23.27M	-$20.04M
Capital Expenditures	$0.00	$0.00	$0.00
Free Cash Flow	-$29.98M	-$23.27M	-$20.04M
YoY Change	135.14%	0.87%	74.11%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2017	us-gaap	Interest Expense Debt InterestExpenseDebt	9494000
CY2017	us-gaap	Investment Income Interest InvestmentIncomeInterest	293000
CY2016	us-gaap	Investment Income Interest InvestmentIncomeInterest	85000
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2789000
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	302000
CY2017Q4	us-gaap	Inventory Net InventoryNet	2657000
CY2015	us-gaap	Interest Expense Debt InterestExpenseDebt	21231000
CY2015	us-gaap	Investment Income Interest InvestmentIncomeInterest	18000
CY2016	us-gaap	Interest Expense Debt InterestExpenseDebt	15576000
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	-350329000
CY2015	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1366000
CY2016	us-gaap	Costs And Expenses CostsAndExpenses	107498000
CY2015	us-gaap	Costs And Expenses CostsAndExpenses	344655000
CY2016	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	14917000
CY2015	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	40960000
CY2017	us-gaap	Costs And Expenses CostsAndExpenses	119934000
CY2015	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-2697000
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-344655000
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	67260000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-117282000
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	125664000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-117333000
CY2016Q4	us-gaap	Assets Current AssetsCurrent	77488000
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	28927000
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	648000
CY2016Q4	us-gaap	Assets Assets	107063000
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3263000
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7937000
CY2016Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	71339000
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	3419000
CY2017Q4	mnkd	Purchase Obligation Current PurchaseObligationCurrent	12131000
CY2016Q4	mnkd	Purchase Obligation Current PurchaseObligationCurrent	5093000
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	87597000
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	92051000
CY2017Q4	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	79666000
CY2016Q4	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	49521000
CY2017Q4	mnkd	Accrued Interest Noncurrent AccruedInterestNoncurrent	2347000
CY2016Q4	mnkd	Accrued Interest Noncurrent AccruedInterestNoncurrent	9281000
CY2017Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	24411000
CY2017Q4	mnkd	Purchase Obligation Noncurrent PurchaseObligationNoncurrent	97585000
CY2016Q4	mnkd	Purchase Obligation Noncurrent PurchaseObligationNoncurrent	95942000
CY2017Q4	us-gaap	Liabilities Liabilities	299307000
CY2016Q4	us-gaap	Liabilities Liabilities	290656000
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	1192000
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	957000
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2638992000
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2553039000
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-18000
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-24000
CY2016Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	27635000
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43946000
CY2018Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	120467137
CY2017Q2	dei	Entity Public Float EntityPublicFloat	103912399
CY2016Q4	us-gaap	Inventory Net InventoryNet	2331000
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-23790000
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-368445000
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22895000
CY2017Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	4409000
CY2017Q4	us-gaap	Other Deferred Costs Net OtherDeferredCostsNet	405000
CY2017	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-13641000
CY2016	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	3433000
CY2017	mnkd	Gain Loss On Purchase Commitments GainLossOnPurchaseCommitments	215000
CY2016	mnkd	Gain Loss On Purchase Commitments GainLossOnPurchaseCommitments	2265000
CY2015	mnkd	Gain Loss On Purchase Commitments GainLossOnPurchaseCommitments	-66167000
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-108189000
CY2016Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	30557000
CY2017	mnkd	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	5488000
CY2016	mnkd	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	5369000
CY2017	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	3782000
CY2016	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	2901000
CY2015	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	2894000
CY2017	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1611000
CY2016	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	72024000
CY2015	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1049000
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	13000
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-597000
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9093000
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	58404000
CY2016Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	16730000
CY2015	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	140412000
CY2016Q4	us-gaap	Other Deferred Costs Net OtherDeferredCostsNet	309000
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3010000
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4364000
CY2017Q4	us-gaap	Assets Current AssetsCurrent	57216000
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	26922000
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	437000
CY2017Q4	us-gaap	Assets Assets	84575000
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6984000
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12449000
CY2017Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	52745000
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	3038000
CY2017Q4	mnkd	Deferred Collaborative Credit Current DeferredCollaborativeCreditCurrent	250000
CY2016Q4	mnkd	Deferred Collaborative Credit Current DeferredCollaborativeCreditCurrent	1000000
CY2016Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	7381000
CY2017Q4	mnkd	Deferred Collaborative Credit Noncurrent DeferredCollaborativeCreditNoncurrent	500000
CY2017Q4	mnkd	Milestone Rights Liability And Other Liabilities Noncurrent MilestoneRightsLiabilityAndOtherLiabilitiesNoncurrent	7201000
CY2016Q4	mnkd	Milestone Rights Liability And Other Liabilities Noncurrent MilestoneRightsLiabilityAndOtherLiabilitiesNoncurrent	8845000
CY2017	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	9192000
CY2016	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1895000
CY2016	mnkd	Net Revenue From Collaboration NetRevenueFromCollaboration	171965000
CY2017	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	2303000
CY2016	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	898000
CY2016	mnkd	Product Costs From Collaboration ProductCostsFromCollaboration	32971000
CY2017	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	14118000
CY2015	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	29674000
CY2017	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	74959000
CY2016	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	46928000
CY2017	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	203000
CY2016	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	1259000
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	51000
CY2016	us-gaap	Net Income Loss NetIncomeLoss	125664000
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-368445000
CY2017	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.13
CY2016	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.37
CY2015	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.54
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-368451000
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2854898000
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2737565000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-214732000
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	-183593000
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	84575000
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	107063000
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	280000000
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	140000000
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	119053414
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	95680831
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	119053414
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	95680831
CY2017	mnkd	Net Revenue From Collaboration NetRevenueFromCollaboration	250000
CY2017	us-gaap	Sales Revenue Net SalesRevenueNet	11745000
CY2016	us-gaap	Sales Revenue Net SalesRevenueNet	174758000
CY2017	us-gaap	Cost Of Goods Sold CostOfGoodsSold	17228000
CY2016	us-gaap	Cost Of Goods Sold CostOfGoodsSold	17121000
CY2015	us-gaap	Cost Of Goods Sold CostOfGoodsSold	64745000
CY2017	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3528000
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	4847000
CY2017	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.13
CY2016	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.36
CY2015	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.54
CY2015	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	887000
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8725000
CY2017	us-gaap	Production Related Impairments Or Charges ProductionRelatedImpairmentsOrCharges	2971000
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3297000
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2331000
CY2017	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	104245000
CY2016	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	92053000
CY2015	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	81233000
CY2017	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	104245000
CY2016	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	92085000
CY2015	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	81233000
CY2017	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	6000
CY2016	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-4000
CY2015	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-6000
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-117327000
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	125660000
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-73770000
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3258000
CY2015	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0
CY2015	mnkd	Stock Issued During Period Value Warrant Exercises StockIssuedDuringPeriodValueWarrantExercises	10123000
CY2015	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-1856000
CY2015	us-gaap	Partners Capital Account Contributions PartnersCapitalAccountContributions	40000
CY2015	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	7926000
CY2015	mnkd	Stock Issued During Period Value Share Lending Agreement StockIssuedDuringPeriodValueShareLendingAgreement	160000
CY2015	mnkd	Adjustments To Additional Paid In Capital Stock Option Issued Upon Debt Conversion AdjustmentsToAdditionalPaidInCapitalStockOptionIssuedUponDebtConversion	169000
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	27843000
CY2015	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	202000
CY2015	mnkd	Adjustments To Additional Paid In Capital Reclassification Of Warrants From Liability To Equity AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityToEquity	109000
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	467000
CY2016	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0
CY2016	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	426000
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5135000
CY2016	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-165000
CY2016	mnkd	Common Stock And Warrants Issued In Direct Placement Value CommonStockAndWarrantsIssuedInDirectPlacementValue	50000000
CY2016	mnkd	Adjustments To Additional Paid In Capital Shares Issued In Private Placement AdjustmentsToAdditionalPaidInCapitalSharesIssuedInPrivatePlacement	-2037000
CY2016	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	12750000
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	24000
CY2017	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	1000
CY2017	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	236000
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4847000
CY2017	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-127000
CY2017	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	21099000
CY2017	mnkd	Common Stock Issued In Direct Placement Value CommonStockIssuedInDirectPlacementValue	61000000
CY2017	mnkd	Adjustments To Additional Paid In Capital Shares Issued In Private Placement AdjustmentsToAdditionalPaidInCapitalSharesIssuedInPrivatePlacement	-3310000
CY2017	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	564000
CY2017	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	17000
CY2017	mnkd	Adjustments To Additional Paid In Capital Reclassification Of Warrants From Liability To Equity AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityToEquity	1893000
CY2017	mnkd	Adjustments To Additional Paid In Capital Amortization Of Shelf Fees AdjustmentsToAdditionalPaidInCapitalAmortizationOfShelfFees	-22000
CY2016	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4158000
CY2015	us-gaap	Depreciation And Amortization DepreciationAndAmortization	13276000
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	5135000
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	8725000
CY2016	us-gaap	Paid In Kind Interest PaidInKindInterest	4478000
CY2015	us-gaap	Paid In Kind Interest PaidInKindInterest	1652000
CY2017	mnkd	Interest On Note Payable To Principal Stockholder InterestOnNotePayableToPrincipalStockholder	3782000
CY2016	mnkd	Interest On Note Payable To Principal Stockholder InterestOnNotePayableToPrincipalStockholder	2901000
CY2015	mnkd	Interest On Note Payable To Principal Stockholder InterestOnNotePayableToPrincipalStockholder	2894000
CY2016	mnkd	Warrant Issuance Costs WarrantIssuanceCosts	653000
CY2017	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-100000
CY2016	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-19000
CY2017	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-203000
CY2016	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-1259000
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2487000
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	302000
CY2017	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	-30557000
CY2016	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	30534000
CY2015	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-140582000
CY2015	us-gaap	Production Related Impairments Or Charges ProductionRelatedImpairmentsOrCharges	36104000
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	26434000
CY2017	mnkd	Increase Decrease In Other Deferred Charges IncreaseDecreaseInOtherDeferredCharges	96000
CY2016	mnkd	Increase Decrease In Other Deferred Charges IncreaseDecreaseInOtherDeferredCharges	309000
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	16675000
CY2015	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-50413000
CY2016	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-13539000
CY2015	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	13539000
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1354000
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	346000
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-13481000
CY2017	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-188000
CY2016	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-361000
CY2015	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-150000
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3800000
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-12118000
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	8413000
CY2017	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2932000
CY2016	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	348000
CY2015	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-12467000
CY2017	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-381000
CY2016	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	3419000
CY2017	us-gaap	Increase Decrease In Customer Advances And Deposits IncreaseDecreaseInCustomerAdvancesAndDeposits	-250000
CY2016	us-gaap	Increase Decrease In Customer Advances And Deposits IncreaseDecreaseInCustomerAdvancesAndDeposits	-134056000
CY2015	us-gaap	Increase Decrease In Customer Advances And Deposits IncreaseDecreaseInCustomerAdvancesAndDeposits	950000
CY2016	mnkd	Increase Decrease In Deferred Collaborative Revenue IncreaseDecreaseInDeferredCollaborativeRevenue	-17503000
CY2015	mnkd	Increase Decrease In Deferred Collaborative Revenue IncreaseDecreaseInDeferredCollaborativeRevenue	17067000
CY2017	mnkd	Increase Decrease In Purchase Commitment Loss IncreaseDecreaseInPurchaseCommitmentLoss	-4745000
CY2016	mnkd	Increase Decrease In Purchase Commitment Loss IncreaseDecreaseInPurchaseCommitmentLoss	40566000
CY2015	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	33000
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-64778000
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-78090000
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-57232000
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1144000
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10285000
CY2017	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	16651000
CY2017	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	24000
CY2016	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	17000
CY2015	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	82000
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1127000
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-10203000
CY2017	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	61000000
CY2016	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	50000000
CY2017	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	3310000
CY2016	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	2690000
CY2017	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	4000000
CY2016	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	5000000
CY2017	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	127000
CY2016	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	165000
CY2015	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1858000
CY2016	mnkd	Proceeds From Issuance Of Common Stock And Warrants Net ProceedsFromIssuanceOfCommonStockAndWarrantsNet	893000
CY2015	mnkd	Proceeds From Issuance Of Common Stock And Warrants Net ProceedsFromIssuanceOfCommonStockAndWarrantsNet	4146000
CY2015	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	10123000
CY2015	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	64287000
CY2015	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	831000
CY2017	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	19429000
CY2015	mnkd	Milestone Payments MilestonePayments	4219000
CY2017	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	564000
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	73563000
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	43038000
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	5668000
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	25460000
CY2016	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-36179000
CY2015	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-61767000
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22895000
CY2015Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	59074000
CY2014Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	120841000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	48355000
CY2017	us-gaap	Income Taxes Paid IncomeTaxesPaid	51000
CY2017	us-gaap	Interest Paid Net InterestPaidNet	7728000
CY2016	us-gaap	Interest Paid Net InterestPaidNet	8991000
CY2015	us-gaap	Interest Paid Net InterestPaidNet	13355000
CY2017	us-gaap	Stock Issued1 StockIssued1	20593000
CY2015	us-gaap	Stock Issued1 StockIssued1	8253000
CY2016	us-gaap	Construction In Progress Expenditures Incurred But Not Yet Paid ConstructionInProgressExpendituresIncurredButNotYetPaid	588000
CY2016	us-gaap	Loans Assumed1 LoansAssumed1	5174000
CY2015	us-gaap	Loans Assumed1 LoansAssumed1	59337000
CY2016	mnkd	Reclassification Of Property Plant And Equipment To Assets Held For Sale Noncash ReclassificationOfPropertyPlantAndEquipmentToAssetsHeldForSaleNoncash	17294000
CY2017	us-gaap	Interest Paid Capitalized InterestPaidCapitalized	10716000
CY2017	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	1880000
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	28392000
CY2017	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	17000
CY2015	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	548000
CY2017	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	24000
CY2015	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	40000
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	355000
CY2017	us-gaap	Revenue Recognition Sales Of Goods RevenueRecognitionSalesOfGoods	<div> <p style="margin-bottom:0pt;margin-top:12pt;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;text-indent:4.25%;">Revenue Recognition – Net Revenue – Commercial Product Sales –<font style="font-style:normal;"> The Company currently sells Afrezza through two channels: wholesale distributors and specialty pharmacies as further described below. The Company provides the right of return for unopened product for a period beginning </font><font style="font-style:normal;">six months prior to and ending twelve months after its expiration date. This right of return is provided to (1) the Company’s wholesale distributors and, through them, to its retail pharmacy customers, and (2) to its specialty pharmacies. Once the product has been prescribed and dispensed to the patient, any right of return ceases to exist.      </font></p> <p style="margin-bottom:0pt;margin-top:6pt;margin-left:6.25%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Sales of Afrezza through Wholesale Distributors<font style="font-style:normal;"> - Between July 1, 2016 and December 15, 2016, the Company sold Afrezza to Integrated Commercialization Solutions Direct (“ICS”) and title and risk of loss transferred to ICS upon shipment. After December 15, 2016, ICS became a third party logistics provider and stopped taking title and risk of loss upon shipment of Afrezza to ICS. The Company sells Afrezza in the United States to wholesale pharmaceutical distributors through ICS, and ultimately to retail pharmacies, which are collectively referred to as “customers”.</font></p> <p style="margin-bottom:0pt;margin-top:6pt;margin-left:6.25%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The current accounting guidance requires the Company to reliably estimate returns in order to recognize revenue upon shipment. While we can currently estimate returns within a range, it is not sufficiently precise to meet the current requirements. Accordingly, the Company defers recognition of revenue on Afrezza product shipments through wholesale distributors until the right of return no longer exists, which occurs at the earlier of the time Afrezza is dispensed from pharmacies to patients or expiration of the right of return. Deferred revenue is presented net of deferred product sales discounts which are further described in <font style="font-style:italic;">Gross-to-net Adjustments</font> below. Through the third quarter of 2017, the Company recognized revenue for wholesale distributors based on Afrezza patient prescriptions dispensed as estimated by syndicated data provided by a third party. The Company also analyzed additional data points to ensure that such third-party data was reasonable, including data related to inventory movements within the channel and ongoing prescription demand. </p> <p style="margin-bottom:0pt;margin-top:6pt;margin-left:6.25%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Change in Estimate – <font style="font-style:normal;">In the fourth quarter of 2017, the Company obtained new and more comprehensive data regarding the inventory in the distribution channel. This data indicated that the amount of inventory in the distribution channel was less than previously estimated. Because the new data was more comprehensive than the data that was previously available to the Company, the Company adjusted the ending gross deferred revenue balance to match the new estimate. In addition to adjusting the gross deferred revenue balance, the Company adjusted the ending balances of deferred discounts and deferred cost of goods sold. The net effect of this change was an increase to net income of $1.2 million or $0.01 basic and diluted net income (loss) per share for the year ended December 31, 2017.</font></p> <p style="margin-bottom:0pt;margin-top:6pt;margin-left:6.25%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Sales of Afrezza through Specialty Pharmacies<font style="font-style:normal;"> - During the first quarter of 2017, the Company began selling Afrezza to a network of specialty pharmacies. Specialty pharmacies generally purchase product on demand.  Title and risk of loss passes to the specialty pharmacies at shipment and our estimated returns are minimal.  Therefore, the Company recognizes revenue for sales through specialty pharmacies at the time the product is shipped to the specialty pharmacies, net of </font>Gross-to-net Adjustments<font style="font-style:normal;"> as described below. For the year ended December 31, 2017, the net amount of revenue recognized from sales to specialty pharmacies was $0.5 million.</font></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.25%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December 31, 2017 and 2016, Afrezza net revenue from commercial product sales consisted of $9.2 million and $1.9 million of net sales, respectively. As of December 31, 2017 and 2016, the ending balances for net deferred revenue, were $3.0 million and $3.4 million, on the Company’s consolidated balance sheets which are presented net of $1.5 million and $0.8 million in deferred gross-to-net adjustments, respectively. The December 31, 2016 deferred revenue balance includes $1.7 million of bulk insulin sales which is described more fully under the heading <font style="font-style:italic;">Revenue Recognition – Revenue – Other</font> below. For the year ended December 31, 2017, shipments to three wholesale distributors represented 89% of total shipments. For the year ended December 31, 2016, the Company sold directly to ICS and Sanofi and for the year ended December 31, 2015 the Company sold directly to Sanofi.</p></div>
CY2017	us-gaap	Revenue Recognition Discounts RevenueRecognitionDiscounts	<div> <p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.25%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;text-indent:4.25%;">Prompt Pay Discounts —<font style="font-style:normal;"> The Company offers cash discounts to its customers, generally </font><font style="font-style:normal;">2% of the sales price, as an incentive for prompt payment. The Company accounts for cash discounts by reducing accounts receivable and deferred revenue by the prompt pay discount amount (at the time of shipment to the wholesale distributor). The Company recognizes the cash discounts as a reduction of revenue in the same period the related revenue is recognized.</font></p> <p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.25%;text-indent:4.25%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Rebates and Chargebacks —<font style="font-style:normal;"> Most of our rebates are contractual or legislatively mandated. Sales rebates include managed care, Medicare, Medicaid, and various other programs. The Company participates in federal and state government-managed Medicare and Medicaid rebate programs and, as such, is required to provide rebates under these programs. Chargebacks are discounts that occur when customers purchase directly from an intermediary wholesale purchaser. </font></p> <p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.25%;text-indent:4.25%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for these rebates and chargebacks by establishing an accrual based on contractual discount rates, expected utilization under each contract and an estimate of the amount of inventory in the distribution channel that will become subject to such rebates and chargebacks based on historical payor data provided by a third-party vendor along with additional data including forecasted participation rate. From that data, as well as input received from the commercial team, an estimated participation rate for each program is determined and applied at the rate for those sales. Any new information regarding changes in the programs’ regulations and guidelines or any changes in the Company’s<font style="font-size:12pt;"> </font>government price reporting calculations that would impact the amount of the rebates will also be taken into account in determining or modifying the appropriate reserve. The time period between the date the product is sold into the channel and the date such rebates may be paid can be up to approximately six to nine months. As such, continuous monitoring of these estimates will be performed on a periodic basis, and if necessary, adjusted to reflect new facts and circumstances. Rebates and chargebacks are recognized as a reduction of revenue in the period the related revenue is recognized.</p></div>
CY2017	us-gaap	Revenue Recognition Deferred Revenue RevenueRecognitionDeferredRevenue	<div> <p style="margin-bottom:0pt;margin-top:12pt;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;text-indent:4.25%;">Deferred Costs from Commercial Product Sales —<font style="font-style:normal;"> Deferred costs from commercial product sales represents the cost of product (including labor, overhead and shipping costs to third party logistics providers) shipped to wholesale distributors, but not dispensed by pharmacies to patients. If the Company estimates that inventory that has been shipped to wholesale distributors will be returned for credit because there is a risk of product expiry, deferred costs of commercial product sales is reduced and cost of goods sold is increased for the cost of such inventory.</font></p></div>
CY2017	us-gaap	Revenue Recognition Multiple Element Arrangements RevenueRecognitionMultipleElementArrangements	<div> <p style="margin-bottom:0pt;margin-top:12pt;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;text-indent:4.25%;">Revenue Recognition — Net Revenue — Collaborations —<font style="font-style:normal;"> The Company enters into collaborations under which we must perform certain obligations and receive periodic payments. The Company evaluates the collaborations under the multiple element revenue recognition accounting guidance. Revenue arrangements with multiple elements are divided into separate units of accounting if certain criteria are met, including whether the delivered elements have stand-alone value to the customer. When deliverables are separable, consideration received is allocated to the separate units of accounting based on the relative selling price of each deliverable and the appropriate revenue recognition principles are applied to each unit. The assessment of multiple element arrangements requires judgment in order to determine the appropriate units of accounting and the points in time that, or periods over which, revenue should be recognized. The terms of and the accounting for the Company’s collaborations are described more fully in Note 8 — Collaboration Arrangements.</font></p></div>
CY2017	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="margin-bottom:0pt;margin-top:12pt;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;text-indent:4.25%;">Concentration of Credit Risk<font style="font-style:normal;"> — Financial instruments which potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. Cash and cash equivalents are held in high credit quality institutions. Cash equivalents consist of interest-bearing money market accounts, which are regularly monitored by management.</font></p></div>
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	598204
CY2016Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	1376000
CY2017Q4	us-gaap	Interest Payable Current InterestPayableCurrent	567000
CY2017Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	157800000
CY2017Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.2
CY2017	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	The Company’s board of directors approved a 1-for-5 reverse stock split of its outstanding common stock. On March 1, 2017, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment of the Company’s Amended and Restated Certificate of Incorporation (the “Charter Amendment”) to effect the 1-for-5 reverse stock split of the Company’s outstanding common stock (the “Reverse Stock Split”) and to reduce the authorized number of shares of the Company’s common stock from 700,000,000 to 140,000,000 shares. The Company’s common stock began trading on the NASDAQ Global Market on a split-adjusted basis when the market opened on March 3, 2017. As a result, all common stock share amounts included in these consolidated financial statements have been retroactively reduced by a factor of five, and all common stock per share amounts have been increased by a factor of five, with the exception of the Company’s common stock par value.
CY2016Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	700000000
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	140000000
CY2017	mnkd	Number Of Wholesale Distributors NumberOfWholesaleDistributors	3
CY2017	mnkd	Percentage Of Product Shipments To Wholesale Distributors PercentageOfProductShipmentsToWholesaleDistributors	0.89
CY2016	mnkd	Deferred Revenue From Sale Of Raw Insulin DeferredRevenueFromSaleOfRawInsulin	1700000
CY2016Q4	us-gaap	Restricted Cash RestrictedCash	0
CY2017Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	572000
CY2017Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1273000
CY2017Q4	us-gaap	Purchase Obligation PurchaseObligation	109300000
CY2015Q4	us-gaap	Purchase Obligation PurchaseObligation	116200000
CY2017	us-gaap	Revenue Recognition Milestone Method Milestone RevenueRecognitionMilestoneMethodMilestone	13
CY2017Q4	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	0
CY2016Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	7400000
CY2015	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	100000
CY2016	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	0
CY2017	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	0
CY2017	us-gaap	Lessee Finance Lease Term Of Contract LesseeFinanceLeaseTermOfContract	P12M
CY2017Q4	us-gaap	Restricted Cash RestrictedCash	4400000
CY2017Q4	mnkd	Cash Discount Percent CashDiscountPercent	0.02
CY2017	mnkd	Deferred Revenue From Sale Of Raw Insulin DeferredRevenueFromSaleOfRawInsulin	0
CY2017	mnkd	Maturity Period Of Cash Equivalents MaturityPeriodOfCashEquivalents	90 days or less at the time of purchase
CY2016	mnkd	Maturity Period Of Cash Equivalents MaturityPeriodOfCashEquivalents	90 days from the date of purchase
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2017Q4	mnkd	Number Of Customers Accounted For Gross Accounts Receivable NumberOfCustomersAccountedForGrossAccountsReceivable	3
CY2016Q4	mnkd	Number Of Customers Accounted For Gross Accounts Receivable NumberOfCustomersAccountedForGrossAccountsReceivable	3
CY2017Q4	mnkd	Percentage Of Accounts Receivable From Major Customers PercentageOfAccountsReceivableFromMajorCustomers	0.93
CY2016Q4	mnkd	Percentage Of Accounts Receivable From Major Customers PercentageOfAccountsReceivableFromMajorCustomers	0.95
CY2017	us-gaap	Inventory Write Down InventoryWriteDown	3000000
CY2016	us-gaap	Inventory Write Down InventoryWriteDown	0
CY2015	us-gaap	Inventory Write Down InventoryWriteDown	39300000
CY2017	mnkd	Percentage Of Credit Exchange Receivable PercentageOfCreditExchangeReceivable	0.65
CY2017Q4	mnkd	Estimated Amounts Credit Exchange Receivable EstimatedAmountsCreditExchangeReceivable	0
CY2016Q4	mnkd	Estimated Amounts Credit Exchange Receivable EstimatedAmountsCreditExchangeReceivable	200000
CY2015Q4	mnkd	Estimated Amounts Credit Exchange Receivable EstimatedAmountsCreditExchangeReceivable	700000
CY2017	mnkd	Long Lived Assets Sale Period LongLivedAssetsSalePeriod	P1Y
CY2017	us-gaap	Asset Impairment Charges AssetImpairmentCharges	200000
CY2016	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1300000
CY2015	us-gaap	Asset Impairment Charges AssetImpairmentCharges	140600000
CY2016Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2120000
CY2017Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	812000
CY2016Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	211000
CY2016	us-gaap	Production Related Impairments Or Charges ProductionRelatedImpairmentsOrCharges	0
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	127874000
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	128502000
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	100952000
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	99575000
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1800000
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2400000
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11000000
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7260000
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3814000
CY2017Q4	mnkd	Current Portion Of Milestone Right Liability CurrentPortionOfMilestoneRightLiability	1643000
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1007000
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	875000
CY2017Q4	mnkd	Customer Discounts And Allowances CustomerDiscountsAndAllowances	873000
CY2016Q4	mnkd	Customer Discounts And Allowances CustomerDiscountsAndAllowances	754000
CY2017Q4	mnkd	Sales And Marketing Related Expenses Accrued SalesAndMarketingRelatedExpensesAccrued	147000
CY2016Q4	mnkd	Sales And Marketing Related Expenses Accrued SalesAndMarketingRelatedExpensesAccrued	144000
CY2017Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	362000
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	1172697
CY2016Q4	us-gaap	Interest Payable Current InterestPayableCurrent	619000
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	590000
CY2017Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	24400000
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1509343
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	6735675
CY2017Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	30000000
CY2017	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	31000
CY2016	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	35000
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum	0.10
CY2015	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	35000
CY2017	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1700000
CY2016	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1722000
CY2015	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1553000
CY2017Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	41000000
CY2016Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	20500000
CY2017Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	93500000
CY2016Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	123200000
CY2017	mnkd	Fair Value Of Liability Percentage Decrease FairValueOfLiabilityPercentageDecrease	0.04
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	280000000
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q4	mnkd	Class Of Warrant Exercise Price Of Warrants Stated As Percentage Of Offering Price ClassOfWarrantExercisePriceOfWarrantsStatedAsPercentageOfOfferingPrice	0.0115
CY2015Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	32000
CY2017Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	13.05
CY2017	mnkd	Class Of Warrant Exercisable Period ClassOfWarrantExercisablePeriod	P5Y
CY2014	mnkd	Common Stock Loaned Under Share Lending Agreement Shares CommonStockLoanedUnderShareLendingAgreementShares	1800000
CY2014	mnkd	Nominal Lending Fee NominalLendingFee	0.05
CY2015Q4	mnkd	Shares Returned Under Share Lending Agreement SharesReturnedUnderShareLendingAgreement	1800000
CY2016	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0
CY2017	mnkd	Class Of Warrants Or Rights Expiration Date ClassOfWarrantsOrRightsExpirationDate	2016-02-08
CY2015Q4	us-gaap	Ownshare Lending Arrangement Shares Outstanding OwnshareLendingArrangementSharesOutstanding	1800000
CY2016	us-gaap	Incremental Common Shares Attributable To Contingently Issuable Shares IncrementalCommonSharesAttributableToContingentlyIssuableShares	32000
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15268444
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16831953
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5980235
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7089440
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1135216
CY2015	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	64245
CY2016	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	104758
CY2017	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	199578
CY2017	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	136660
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4847000
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5135000
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8725000
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0183
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0118
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0161
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0213
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0180
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0186
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.8332
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.7757
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.6976
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.9039
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.8275
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.7184
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5530256
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3335385
CY2017	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	5300
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2813227
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.33
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	9.70
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	16.10
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.60
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.55
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.17
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	22.21
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	19.52
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2484000
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	2262000
CY2017Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	61000
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.19
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.05
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	12.80
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	6200000
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	20000
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	500000
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3300000
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y10M13D
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y9M
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y6M25D
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	737966
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	669091
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	192361
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	79480
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	8.40
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.36
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	10.02
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	5.89
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	4.08
CY2017Q4	mnkd	Share Based Compensation Arrangement Restricted Stock Units Number Of Units Expected To Vest ShareBasedCompensationArrangementRestrictedStockUnitsNumberOfUnitsExpectedToVest	939240
CY2017Q4	mnkd	Weighted Average Grant Date Fair Value Of Restricted Stock Units Expected To Vest WeightedAverageGrantDateFairValueOfRestrictedStockUnitsExpectedToVest	4.28
CY2017	mnkd	Value Of Restricted Stock Units Vested ValueOfRestrictedStockUnitsVested	2200000
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	400000
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	600000
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	5200000
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	1900000
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	2600000
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	5500000
CY2017	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y3M18D
CY2017	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	90300000
CY2017Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	8900000
CY2017Q4	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	11600000
CY2017Q4	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	15500000
CY2017Q4	us-gaap	Purchase Obligation Due In Fourth Year PurchaseObligationDueInFourthYear	15500000
CY2017Q4	us-gaap	Purchase Obligation Due In Fifth Year PurchaseObligationDueInFifthYear	19400000
CY2017Q4	mnkd	Purchase Obligation Due In Sixth Year PurchaseObligationDueInSixthYear	19400000
CY2017Q4	mnkd	Purchase Obligation Included In Accounts Payable PurchaseObligationIncludedInAccountsPayable	1600000
CY2017	mnkd	Long Term Purchase Commitment Cancellation Fees LongTermPurchaseCommitmentCancellationFees	1400000
CY2017	mnkd	Long Term Purchase Commitment Expiration Date LongTermPurchaseCommitmentExpirationDate	2023-12-31
CY2017	mnkd	Longterm Purchase Commitment Renewal Time Period LongtermPurchaseCommitmentRenewalTimePeriod	P2Y
CY2017	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	400000
CY2016	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	400000
CY2015	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	400000
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	522000
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	947000
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	976000
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	1005000
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	1035000
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	88000
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	4573000
CY2016	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-4311000
CY2017	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2016	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2015	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2017	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	260199000
CY2017	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	400000
CY2016	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	400000
CY2015	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	600000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-113679000
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	129361000
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-358047000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-3603000
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-3697000
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-10398000
CY2017	mnkd	Income Tax Expense Benefit Net IncomeTaxExpenseBenefitNet	51000
CY2016	mnkd	Income Tax Expense Benefit Net IncomeTaxExpenseBenefitNet	0
CY2015	mnkd	Income Tax Expense Benefit Net IncomeTaxExpenseBenefitNet	0
CY2017	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	51000
CY2016	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2015	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2017	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2016	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2015	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2017	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0
CY2016	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0
CY2015	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0
CY2017	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	51000
CY2016	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0
CY2015	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0
CY2017	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	244801000
CY2016	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-43814000
CY2015	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	109512000
CY2017	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	15398000
CY2016	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	-48125000
CY2015	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	80118000
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-260199000
CY2016	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	48125000
CY2015	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-80118000
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	507235000
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	712124000
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	83461000
CY2016Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	77998000
CY2017Q4	mnkd	Deferred Tax Assets Capitalized Research Expenses DeferredTaxAssetsCapitalizedResearchExpenses	1016000
CY2016Q4	mnkd	Deferred Tax Assets Capitalized Research Expenses DeferredTaxAssetsCapitalizedResearchExpenses	5117000
CY2017Q4	mnkd	Deferred Tax Assets Milestone Rights DeferredTaxAssetsMilestoneRights	1908000
CY2016Q4	mnkd	Deferred Tax Assets Milestone Rights DeferredTaxAssetsMilestoneRights	3242000
CY2017Q4	mnkd	Deferred Tax Assets Tax Deferred Expense Accrual Adjustment DeferredTaxAssetsTaxDeferredExpenseAccrualAdjustment	211000
CY2016Q4	mnkd	Deferred Tax Assets Tax Deferred Expense Accrual Adjustment DeferredTaxAssetsTaxDeferredExpenseAccrualAdjustment	440000
CY2017Q4	mnkd	Deferred Tax Assets Loss On Purchase Commitment DeferredTaxAssetsLossOnPurchaseCommitment	23654000
CY2016Q4	mnkd	Deferred Tax Assets Loss On Purchase Commitment DeferredTaxAssetsLossOnPurchaseCommitment	36775000
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	7004000
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	17331000
CY2017Q4	mnkd	Deferred Tax Assets Capitalized Costs DeferredTaxAssetsCapitalizedCosts	5194000
CY2016Q4	mnkd	Deferred Tax Assets Capitalized Costs DeferredTaxAssetsCapitalizedCosts	8781000
CY2016Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	45310000
CY2017Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	0
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	795000
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	7380000
CY2017Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	23820000
CY2016Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350
CY2017	mnkd	Effective Income Tax Rate Reconciliation Permanent Items EffectiveIncomeTaxRateReconciliationPermanentItems	0.062
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.00
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.009
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.010
CY2017	mnkd	Effective Income Tax Rate Reconciliation Effect Of Tax Law Changes EffectiveIncomeTaxRateReconciliationEffectOfTaxLawChanges	-2.650
CY2016	mnkd	Effective Income Tax Rate Reconciliation Effect Of Tax Law Changes EffectiveIncomeTaxRateReconciliationEffectOfTaxLawChanges	0.00
CY2015	mnkd	Effective Income Tax Rate Reconciliation Effect Of Tax Law Changes EffectiveIncomeTaxRateReconciliationEffectOfTaxLawChanges	0.00
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.050
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.00
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.00
CY2017	mnkd	Effective Income Tax Rate Reconciliation Expirations Of Attribute EffectiveIncomeTaxRateReconciliationExpirationsOfAttribute	-0.028
CY2016	mnkd	Effective Income Tax Rate Reconciliation Expirations Of Attribute EffectiveIncomeTaxRateReconciliationExpirationsOfAttribute	0.00
CY2015	mnkd	Effective Income Tax Rate Reconciliation Expirations Of Attribute EffectiveIncomeTaxRateReconciliationExpirationsOfAttribute	0.00
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	2.316
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.340
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.340
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00
CY2017	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-260200000
CY2016	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-48100000
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	2000000000
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	2200000000
CY2004Q3	mnkd	Operating Loss Carryforwards Subject To Limitation OperatingLossCarryforwardsSubjectToLimitation	216000000
CY2004Q3	mnkd	Net Operating Loss Carryforward Annual Limitation NetOperatingLossCarryforwardAnnualLimitation	13000000
CY2017Q4	mnkd	Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit	0
CY2017	mnkd	Tax Cuts And Jobs Act Of2017 Decrease In Employee Remuneration TaxCutsAndJobsActOf2017DecreaseInEmployeeRemuneration	301000000
CY2017	mnkd	Tax Cuts And Jobs Act Of2017 Decrease In Valuation Allowance TaxCutsAndJobsActOf2017DecreaseInValuationAllowance	301000000
CY2017	mnkd	Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit	0
CY2017	mnkd	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Transition Tax For Accumulated Foreign Earnings Provisional Income Tax Expense TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalIncomeTaxExpense	0
CY2016Q2	us-gaap	Stock Issued1 StockIssued1	44700000
CY2016Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.50
CY2017Q3	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	1900000
CY2017Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	32000
CY2015Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	3028000
CY2016	us-gaap	Restructuring Charges RestructuringCharges	2035000
CY2016	us-gaap	Restructuring Reserve Settled Without Cash2 RestructuringReserveSettledWithoutCash2	3687000
CY2017	us-gaap	Restructuring Reserve Settled Without Cash2 RestructuringReserveSettledWithoutCash2	1014000
CY2017Q1	us-gaap	Sales Revenue Net SalesRevenueNet	3009000
CY2017Q2	us-gaap	Sales Revenue Net SalesRevenueNet	2163000
CY2016Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	95627000
CY2017Q3	us-gaap	Sales Revenue Net SalesRevenueNet	2043000
CY2017Q4	us-gaap	Sales Revenue Net SalesRevenueNet	4530000
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-16324000
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-35339000
CY2016Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.56
CY2016Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	85771000
CY2016Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	91061000
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-32886000
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	-32784000
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2017Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.35
CY2017Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
CY2017Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.28
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2017Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.35
CY2017Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.31
CY2017Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.28
CY2017Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	95744000
CY2017Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	99864000
CY2017Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	104703000
CY2017Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	116451000
CY2017Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	95744000
CY2017Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	99864000
CY2017Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	104703000
CY2017Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	116451000
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	162354000
CY2016Q4	us-gaap	Sales Revenue Net SalesRevenueNet	12404000
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-24873000
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-29959000
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	126520000
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	53976000
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2016Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.32
CY2016Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.56
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.29
CY2016Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.33
CY2016Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.31
CY2016Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	95676000
CY2016Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	85771000
CY2016Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	91061000
CY2016Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	96548000
CY2016Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	96510000
CY2017Q4	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1200000

Files In Submission

Name	View Source	Status
0001564590-18-003510-index-headers.html	Edgar Link	pending
0001564590-18-003510-index.html	Edgar Link	pending
0001564590-18-003510.txt	Edgar Link	pending
0001564590-18-003510-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g2018022720575325023313.jpg	Edgar Link	pending
g2018022720575355424143.jpg	Edgar Link	pending
g2018022720575366322548.jpg	Edgar Link	pending
g2018022720575369122549.jpg	Edgar Link	pending
g2018022720585404224144.jpg	Edgar Link	pending
g2018022720585766423772.jpg	Edgar Link	pending
mnkd-10k_20171231.htm	Edgar Link	pending
mnkd-20171231.xml	Edgar Link	completed
mnkd-20171231.xsd	Edgar Link	pending
mnkd-20171231_cal.xml	Edgar Link	unprocessable
mnkd-20171231_def.xml	Edgar Link	unprocessable
mnkd-20171231_lab.xml	Edgar Link	unprocessable
mnkd-20171231_pre.xml	Edgar Link	unprocessable
mnkd-ex1016_443.htm	Edgar Link	pending
mnkd-ex1047_871.htm	Edgar Link	pending
mnkd-ex104_445.htm	Edgar Link	pending
mnkd-ex105_446.htm	Edgar Link	pending
mnkd-ex106_444.htm	Edgar Link	pending
mnkd-ex231_696.htm	Edgar Link	pending
mnkd-ex311_697.htm	Edgar Link	pending
mnkd-ex312_700.htm	Edgar Link	pending
mnkd-ex321_699.htm	Edgar Link	pending
mnkd-ex322_698.htm	Edgar Link	pending
mnkd-ex51_888.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MNKD
MANNKIND CORP Stock $mnkd

2017 Q4 Form 10-K Financial Statement

#000156459018003510 Filed on February 27, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MNKD MANNKIND CORP Stock $mnkd

2017 Q4 Form 10-K Financial Statement

#000156459018003510 Filed on February 27, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MNKD
MANNKIND CORP Stock $mnkd